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Abstract
Prostate cancer (PCA) is the most common invasive
malignancy and the second leading cause of cancer-
related deaths in the USmale population. One approach
to control this malignancy is its preventive intervention
by dietary agents. Inositol hexaphosphate (IP6), a diet-
ary constituent, has shown promising efficacy against
various cancers; however, limited studies have been
performed with IP6 against PCA. Here, we investigated
the growth-inhibitory effect and associated mecha-
nisms of IP6 in androgen-dependent human prostate
carcinomaLNCaPcells. IP6 treatment of cells resulted in
a strong growth inhibition and an increase in G1 cell
population. In mechanistic studies, IP6 resulted in an
increase in cyclin-dependent kinase inhibitors (CDKIs)
Cip1/p21 and Kip1/p27 levels, together with a decrease
in cyclin-dependent kinase (CDK) 4 and cyclin D1 pro-
tein levels. An increase in CDKI levels by IP6 also led to
a concomitant increase in their interactions with CDK2
and CDK4, together with a strong decrease in the kinase
activity of both CDKs. Downstream in CDKI–CDK–
cyclin cascade, consistent with its inhibitory effect on
CDK kinase activity, IP6 treatment of cells increased
hypophosphorylated levels of retinoblastoma (Rb) with
a decrease in Rb phosphorylation at serine 780, 807, and
811 sites, and caused a moderate to strong decrease in
the levels of transcription factors E2F1, E2F4, and E2F5.
In other studies, IP6 caused a dose- and a time-depend-
ent apoptotic death of LNCaP cells, and a decrease in
Bcl2 levels, causing a strong increase in Bax versus
Bcl2 ratio, aswell as an inhibitionof constitutively active
AKT phosphorylation. Taken together, these molecular
alterations provide an insight into IP6-caused growth
inhibition, G1 arrest, and apoptotic death of human
prostate carcinoma LNCaP cells. Because early clinical
PCA growth is an androgen-dependent response, the
results of the present study employing androgen-
dependent LNCaP cells suggest that IP6 has promise
and potential to be effective against PCA.
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Introduction
Statistics of prostate cancer (PCA) show that it is the second
most common male malignancy in the United States and
European countries [1]. It is estimated that 220,900 new cases
and 28,900 associated deaths would have occurred from PCA
in 2003 [1]. In the genesis of PCA, a variety of pathogenetic
pathways/factors exist, and the rates of PCA differ up to 90-fold
between different populations [2–4]. Both epidemiological and
laboratory studies suggest that diet and androgen increase
PCA risk through a common etiologic pathway [3–6]. Impor-
tantly, several studies in recent years have also shown that diet
and nutrition play a significant role in PCA control, prevention,
and/or intervention, and, accordingly, extensive efforts are
being made for the prevention/intervention of PCA by altering
dietary choices or the use of dietary supplements [7–9].
Inositol hexaphosphate (IP6), also known as phytic acid, is
one such dietary agent, which is described as ‘‘natural cancer
fighter,’’ being an important constituent of natural diets. It is
found in abundance in high-fiber-content diets [10]. Most
cereals, legumes, nuts, oil seeds, and soybean contain 0.5%
to 6.4% (wt/wt) or even higher levels of IP6 [10]. In an animal
study, it has been reported that physiological levels of IP6 are
more dependent on consumption of IP6-rich diet compared to
the levels of its lower phytate derivatives, IP5 and IP4 [11].
Another study suggests that humans become deficient in IP6
if they consume IP6-poor diet for as little as 2 weeks [12].
Almost three decades of research with IP6 have revealed its
broad-spectrum antineoplastic activities in different cancer
models (reviewed in Refs. [10,13]). In cell culture, IP6 has
been shown to inhibit: 1) growth of human breast, colon, and
liver cancer cells, and rhabdomyosarcoma and erythroleuke-
mia cells; and 2) cell transformation in mouse epidermal JB6
cells [14–19]. IP6 has also been shown to impair epidermal
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growth factor (EGF) or phorbol ester– induced ERK1/2-AP1
activation and phosphotidylinositol-3 kinase (PI-3K) activity
in JB6 cells as its anti– tumor promotion mechanism [19].
However, there are only a few studies showing the antican-
cer potential of IP6 against PCA cells; these reports em-
ployed advanced and androgen-independent human PCA
cell lines PC3 and DU145. The first study reported that IP6
inhibits growth and induces differentiation of human PCA
PC-3 cells [20]. More recently, we showed that IP6 impairs
erbB1 receptor–associated mitogenic signaling [21], and
induces G1 arrest in cell cycle progression and modulates
cell cycle regulatory proteins in DU145 cells [22]. Most of the
abovementioned in vitro studies have used up to 5 mM IP6.
With regard to in vivo anticancer efficacy of IP6, it has
been shown that 1% IP6 in drinking water 1 week before or
2 weeks after the administration of azoxymethane inhibits
the development of large intestinal cancer in F344 rats [23].
Later, it was reported that in same animal model, treatment
with 2% IP6 in drinking water, even after 5 months of car-
cinogen induction, significantly inhibits both number and size
of tumors in large intestines [24]. IP6 was also found to
suppress dimethylhydrazine-induced large intestinal cancer
in CD-1 mice [25]. Furthermore, IP6 has been shown to:
1) inhibit DMBA-induced rat mammary cancer growth [26];
2) regress liver cancer xenotransplant [27]; 3) prevent pul-
monary adenomas in mice [28]; 4) prevent DMBA-induced
skin tumorigenesis [29]; 5) inhibit the growth of rhabdomyo-
sarcoma tumor xenograft growth [16]; 6) inhibit the growth of
mouse fibrosarcoma FSA-1 tumor xenografts in nude mice
[30]; and 7) inhibit colon carcinogenesis [31,32]. In another
study, it is reported that IP6 treatment reveres the colon
carcinogen (dimethylhydrazine)– induced suppression of
natural killer cells activity, as well as enhances the baseline
natural killer cells’ cytotoxicity in mice [33]. With regard to
PCA, only very recently did we report, for the first time, that
1% and 2% (wt/vol) IP6 feeding in drinking water inhibits
DU145 tumor xenograft growth in athymic nude mice, which
was associated with anti–proliferative, pro–apoptotic, and
anti–angiogenic effects of IP6 in the tumor xenograft [34].
Various animal studies reported above, including ours, have
also shown that IP6 does not cause any noticeable harmful
side effects or toxicity even at higher doses (up to 2% wt/vol
or 15 mM in drinking water) and chronic administration
[24,34,35]. With regard to epidemiological studies with IP6,
consumption of IP6-rich cereals and legumes has been
suggested to be associated with a reduction in prostate,
breast, and colon, cancers [12].
The induction of PCA in humans has been viewed as a
multistage process involving progression from low-grade
small latent carcinoma to higher-grade large metastasizing
carcinoma [36]. PCA growth and progression involve differ-
ent molecular events converging into an aberrant (deregu-
lated) cell cycle progression and loss of apoptosis of
transformed and cancerous prostate cells [36]. The defects
in cell cycle progression in cancer cells, including PCA, also
involve altered expression, interaction, and/or function of
different cell cycle regulators [36–39]. A controlled cell cycle
progression is regulated by cyclin-dependent kinases
(CDKs), the activities of which are positively regulated by
interactions with their regulatory subunits—cyclins [36–39].
There are numerous evidences, however, showing an over-
expression of cyclins and/or CDKs in many human cancers
and derived cell lines, including PCA [36–39]. The other im-
portant regulators in a controlled cell cycle progression
are cyclin-dependent kinase inhibitors (CDKIs), such as
Cip1/p21, Kip1/p27, and Kip2/p57, which control CDK kinase
activity in response to both mitogenic and growth-inhibitory
signals [36–43]. Frequent mutations in CDKIs or a lack
of their expression have been shown to be another com-
mon feature in the majority of human cancers including
PCA [36–39]. Taken together, these studies clearly suggest
that a controlled regulation of cell cycle progression by an
increase in expression and function of CDKIs, causing a
decrease in CDK kinase activity and associated downstream
events, could be an effective approach to control the growth
and proliferation of PCA cells and facilitate their apoptotic
death [44].
Because clinical PCA is initially androgen-dependent for
its growth [36], employing androgen-dependent human pros-
tate carcinoma LNCaP cells as a model system, in the pre-
sent study, we assessed the efficacy of IP6 on cell growth,
cell cycle progression, and apoptotic death, and associated
mechanisms. The results obtained demonstrate that IP6 in-
hibits LNCaP cell growth, together with G1 arrest, through an
induction in Cip1/p21 and Kip1/p27 levels, causing their
increased interaction with CDKs and leading to a decrease
in kinase activity toward retinoblastoma (Rb) phosphoryl-
ation. IP6 also showed the apoptotic death of LNCaP cells
that was associated with a decrease in Bcl2, concomitant
with an increase in Bax versus Bcl2 levels and an inhibition in
constitutively active survival factor AKT favoring apoptotic
response.
Materials and Methods
Cell Lines and Reagents
The human prostate carcinoma cell line LNCaP was
obtained from American Type Culture Collection (Manassas,
VA). Cells were cultured in RPMI 1640 with 10% fetal bovine
serum (Hyclone, Logan, UT) and 1% penicillin–streptomycin
under standard culture conditions (37jC, 95% humidified air,
and 5% CO2). IP6 and anti–actin antibody were from Sigma-
Aldrich Chemical Co. (St. Louis, MO). RPMI 1640 and
other culture materials were from Life Technologies, Inc.
(Gaithersburg, MD). Anti –Cip1/p21 antibody was from
Calbiochem (Cambridge, MA), and anti–Kip1/p27 antibody
was from Neomarkers, Inc. (Fremont, CA). Antibodies to
CDK2 and CDK4; cyclins D1 and E; E2F1, E2F2, E2F3,
E2F4, and E2F5; and Rb (recognizes both hyperphosphoryl-
ated and hypophosphorylated Rb forms as slow-migrating
and fast-migrating bands, respectively) were from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Histone H1 was
from Boehringer Mannheim Corp. (Indianapolis, IN). [g-32P]
ATP (specific activity, 3000 Ci/mmol); anti–mouse horse-
radish peroxidase–conjugated secondary antibody and ECL
detection system were from Amersham Corp. (Arlington
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Heights, IL). The phospho-specific Rb antibodies, phospho-
AKT and total AKT antibodies, Rb-C fusion protein, and
anti–goat anti–rabbit immunoglobulin horseradish peroxi-
dase–conjugated secondary antibody were from Cell Sig-
naling Technology (Beverly, MA). Cell Death Detection
ELISAplus kit was from Roche Diagnostics (Indianapolis,
IN). Other chemicals were obtained in their commercially
available highest purity grade.
Cell Growth Assay
LNCaP cells were plated at 5000 cells/cm2 in 60-mm
plates under standard culture conditions detailed above for
24 hours. Thereafter, cells were fed with fresh medium and
treated with various doses (0.5–4 mM, final concentration
in the medium) of IP6 dissolved in distilled water and
pH-adjusted (7.4). The doses of IP6 selected in this study
are those used by others and us in several studies [19–22].
After 24 and 48 hours, cells were collected by a brief
trypsinization, and counted in duplicate with a hemocyto-
meter. Each treatment and time point had three independent
plates. The representative data shown in this study were
reproducible in an additional independent experiment.
Fluorescence-Activated Cell Sorter (FACS) Analysis for
Cell Cycle Phase Distribution
LNCaP cells were grown under 10% serum conditions
in RPMI 1640 medium as detailed above. In the first exper-
iment, cells were treated with 0.5 to 4 mM IP6 for 24 and
48 hours and, in the second experiment, with 1 and 2 mM
IP6 for 6, 12, and 24 hours. At the end of each treatment,
cells were collected after a brief incubation with trypsin–
EDTA followed by processing for cell cycle analysis. Briefly,
0.5  105 cells were suspended in 0.5 ml of saponin/pro-
pidium iodide (PI) solution [0.3% saponin (wt/vol), 25 mg/ml
PI (wt/vol), 0.1 mM EDTA, and 10 mg/ml RNase (wt/vol) in
PBS] and incubated overnight at 4jC in the dark. Cell cycle
distribution was then analyzed by flow cytometry using the
FACS analysis core facility of the University of Colorado
Cancer Center (Denver, CO). Finally, the percentage of
cells in different phases of cell cycle was determined by
ModFit LT cell cycle analysis software. In both experiments,
each treatment and time point had three independent plates.
The representative data shown in this study were reproduc-
ible in an additional independent experiment.
Cell Culture Treatments for Molecular Analyses
LNCaP cells were cultured in RPMI 1640 medium con-
taining 10% fetal bovine serum and 1% penicillin–strepto-
mycin under standard culture conditions. At 60% confluency,
cultures were treated with different doses of IP6 (1, 2, and
4 mM) for desired time periods. After these treatments, cell
lysates were prepared in nondenaturing lysis buffer (10 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 1 mM EGTA, 0.3 mM phenyl methyl sulfonyl fluoride,
0.2 mM sodium orthovanadate, 0.5% NP-40, and 5 U/ml
aprotinin). Briefly, the medium was aspirated and cells were
washed with ice-cold PBS for two times followed by incuba-
tion in lysis buffer for 10 minutes on ice. Then cells were
scrapped and kept on ice for 30 minutes, and, finally, cell
lysates were cleared by centrifugation at 4jC for 30 minutes
at 14,000 rpm. Protein concentrations in lysates were deter-
mined using Bio-Rad DC protein assay kit (Bio-Rad Labora-
tories, Hercules, CA).
Immunoprecipitation and Immunoblotting
Cell lysates (200 mg of proteins per sample) were diluted
to 1 ml with lysis buffer, precleared with protein A/G plus
agarose for 1 hour, then incubated overnight with primary
antibody against Cip1/p21 or Kip1/p27 plus protein A/G plus
agarose beads; and immunocomplexes were collected and
washed three times with lysis buffer. For immunoblotting,
immunocomplexes or total cell lysates were denatured with
2 sample buffer. Samples were subjected to SDS-PAGE
on 12% or 16% gel and separated proteins were transferred
onto membrane by Western blot analysis. Membranes were
blocked with blocking buffer for 1 hour at room temperature
and, as desired, probed with primary antibody against Cip1/
p21, Kip1/p27, CDK2, CDK4, cyclin E, cyclin D1, total Rb,
phospho-specific Rb, E2F1, E2F2, E2F3, E2F4, E2F5, Bax,
Bcl2, total AKT, phospho-AKT, and b-actin overnight at 4jC
followed by peroxidase-conjugated appropriate secondary
antibody and ECL detection.
Kinase Assays
To assess CDK4 kinase activity, 200 mg of protein lysate
from each sample was precleared with protein A/G plus
agarose beads and CDK4 protein was immunoprecipitated
using anti–CDK4 antibody and protein A/G plus agarose
beads. After overnight incubation at 4jC, beads conjugated
with antibody and protein were washed three times with
Rb lysis buffer (50 mMHEPES–KOH, pH 7.5, 150 mMNaCl,
1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 80 mM b-glycer-
ophosphate, 1 mM NaF, 0.1 mM sodium orthovanadate,
0.1% Tween 20, 10% glycerol, 1 mM PMSF, and 10 mg/ml
aprotinin and leupeptin) and twice with Rb kinase assay
buffer (50 mM HEPES–KOH, pH 7.5, 2.5 mM EGTA, 1 mM
DTT, 10 mM b-glycerophosphate, 10 mM MgCl2, 1 mM NaF,
and 0.1 mM sodium orthovanadate). Phosphorylation of
Rb was measured by incubating the beads with 30 ml of
Rb kinase solution (1 mg of Rb fusion protein and 0.1 mM
ATP in Rb kinase buffer) for 30 minutes at 37jC. Reaction
was stopped by boiling the samples in 5 SDS sample buffer
for 5 minutes. Samples were analyzed by SDS-PAGE
and Western blot analysis followed by detection of Rb fu-
sion protein phosphorylation employing phospho-specific
Rb antibodies.
Similarly, to determine the CDK2-associated H1 histone
kinase activity, CDK2 protein was immunoprecipitated using
anti–CDK2 antibody and protein A/G plus agarose beads.
Beads were washed two times with lysis buffer and, finally,
once with kinase assay buffer (50 mM Tris–HCl, pH 7.4,
10 mM MgCl2, and 1 mM DTT). Phosphorylation of histone
H1 was measured by incubating the beads with 30 ml of hot
kinase solution [2.5 mg of histone H1, 0.5 ml (5 mCi) of [g-32P]
ATP, 0.5 ml of 0.1 mM ATP, and 28.75 ml of kinase buffer] for
30 minutes at 37jC. The samples were then boiled in
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SDS sample buffer for 5 minutes to stop the reaction and
subjected to 12% SDS-PAGE, and the gel was dried and
analyzed by autoradiography.
Quantitative Apoptotic Cell Death Assay
To quantify IP6-induced apoptotic death of LNCaP cells,
cells were cultured and treated with IP6 at 1, 2, or 4 mM dose
for various time points (1– 48 hours) as detailed above. After
these treatments, cells were harvested and processed for
the analysis of apoptotic DNA fragments using Cell Death
Detection ELISAplus kit and following the step-by-step pro-
tocol provided by the vendor. This method detects the
mononucleosomal and oligonucleosomal DNA fragments
released into the cytoplasm using anti–DNA–POD and
anti–histone–biotin antibodies. Quantitative ELISA at OD
405 to 490 nm then measures subsequent color formation
after the addition of ABTS substrate. Enrichment factor (EF)
was calculated using the formula: EF = absorbance of
treated sample/absorbance of corresponding untreated
sample. In other experiments, LNCaP cells were cultured
under standard culture conditions and, atf80% confluency,
were treated with PI-3K inhibitor LY294002, EGF, and IP6
either alone or LY294002 plus EGF and IP6 plus EGF for
12 or 24 hours in serum-free medium. After these treat-
ments, cells were harvested and processed for the analysis
of apoptotic DNA fragments using Cell Death Detection
ELISAplus kit, as detailed above.
Densitometry and Statistical Analysis
Autoradiograms and immunoblots were scanned with
Adobe Photoshop 6.0 (Adobe Systems, Inc., San Jose,
CA). The density for each band in immunoblotting, binding,
and kinase activity assays was analyzed using the Scion
Image program, National Institutes of Health (Bethesda,
MD). The numerical data discussed in the Results section
for an observed change in a specific molecule are based on
the densitometric analyses of bands in different studies. In
each case, these numbers and associated discussions are
based on the observations from two to three independent
experiments. Statistical significance of differences between
control and treated samples was calculated by Student’s
t test (SigmaStat 2.0; Jandel Scientific, San Rafeal, CA).
P values of less than .05 were considered statistically
significant.
Results
Effect of IP6 on Growth and Cell Cycle Progression of
LNCaP Cells
First, studies were performed to assess the effects of
IP6 on LNCaP cell growth. The cells were seeded and
treated 24 hours later with varying doses of IP6 for 24 or
48 hours, and the total number of cells was counted manually
by hemocytometer. As shown in Figure 1, treatment of cells
with IP6 resulted in a moderate to strong cell growth inhibi-
tion at both 24 and 48 hours of treatment. Overall, 0.5 to
4 mM IP6 doses resulted in a 23%, 19%, 29%, and 58%
decrease (P < .01 to P < .001) in LNCaP cell growth follow-
ing 24 hours of treatment, and 44%, 50%, 38%, and 63%
growth inhibition (P < .01 to P < .001) after 48 hours of treat-
ment, respectively (Figure 1).
Because cell cycle progression is an essential event for
cellular growth, based on our results showing that IP6
causes cell growth inhibition, we next examined whether this
effect of IP6 is mediated through an alteration in a specific
phase of the cell cycle progression. For this experiment,
identical IP6 treatments were performed as for cell growth
study, and cell cycle progression was studied by FACS anal-
ysis following saponin/PI staining. As shown in Figure 2,
IP6 treatment for 24 hours resulted in a moderate to strong
increase in G1 cell population in a dose-dependent man-
ner; however, it showed only moderate response following
48 hours of similar treatment. Compared to controls showing
66.5% cells in G1 phase at 24 hours, IP6 treatment at 0.5,
1, 2, or 4 mM doses resulted in 69.2 (P < .05), 70.9 (P < .01),
74.9 (P < .01), and 81.9% (P < .001) cells in the G1 phase of
the cell cycle, respectively (Figure 2A). The observed ac-
cumulation of the cells in G1 phase by IP6 was accompanied
by a decrease in both S phase (Figure 2B) and G2/M phase
(Figure 2C ) in a dose-dependent manner. Because we did
not observe any affect of IP6 on cell cycle progression
following 48 hours of its treatment, an additional experiment
was next conducted at early time points to seek a time
kinetics of G1 arrest by IP6. As shown in Figure 2D, IP6
treatment of cells at 1 and 2 mM doses, which showed a
strong G1 arrest in 24 hours of treatment (Figure 2A),
resulted in no changes following 6 hours of treatment, but
caused a G1 arrest in cell cycle progression at 12 and 24
hours of its treatment, which was consistent with a decrease
in both S and G2/M phase cell populations (Figure 2, E and
F ), as observed in the first experiment (Figure 2, B and C ).
Together, these results suggested that IP6 causes a strong
G1 arrest in the cell cycle progression of LNCaP cells, and
that such an affect is evident as early as 12 hours of its
treatment. These observations also suggested that IP6-
caused G1 arrest might possibly be involved in its growth-
inhibitory efficacy in LNCaP cells.
Figure 1. Effect of IP6 on LNCaP cell growth. Cells were plated at 5000 cells/
cm2 in 60-mm plates under standard culture conditions and, 24 hours later,
fed with fresh medium and treated with various doses of IP6 as detailed in
Materials and Methods section. After 24 and 48 hours, cells were collected by
a brief trypsinization and counted in duplicate with a hemocytometer. The
data shown are mean ± SE of three independent plates, which were
reproducible in an additional independent experiment.
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Effect of IP6 on G1 Cell Cycle Regulators in LNCaP Cells
The levels, interactions, and kinase activities of CDK cy-
clins drive an overall cell cycle progression, where G1 to
S phase transition is mediated by CDK4/cyclin D1 at early
G1 and by CDK2/cyclin E during late G1 to S phase
[36–40,44]. The other major regulator of cell cycle transi-
tions is CDKI, whose level and interaction with CDK cyclin
govern a controlled (in normal cell) or an uncontrolled (in
transformed and cancerous cells) cell cycle progression
[36–40,44]. The two important CDKIs are Cip1/p21, which
regulates all phases of the cell cycle, and Kip1/p27, which
specifically controls G1 phase [40–44]. Based on our find-
ings showing a moderate to strong increase in G1 phase
cell population following IP6 treatment of cells as early as
12 hours and sustained up to 24 hours, we next assessed
the mechanism of this affect of IP6 under similar treat-
ment conditions. First, studies were performed to assess
whether IP6 causes an alteration in CDKIs Cip1/p21 and
Kip1/p27. As shown in Figure 3, compared to controls, IP6
treatment of cells resulted in a moderate to strong increase in
the protein levels of both Cip1/p21 (Figure 3A) and Kip1/p27
(Figure 3B) in a dose-dependent manner, where 12 hours
of treatment time showed more induction in these CDKIs
compared to 24 hours of exposure. In other studies as-
sessing the effect of IP6 on CDK and cyclin levels, as shown
in Figure 3, C and D, IP6 treatment of LNCaP cells showed
a moderate decrease in CDK2 protein levels (f20–30%
decrease compared to control), but caused a stronger de-
crease in CDK4 levels (f40–50% decrease compared to
control) at all doses and time points studied. A similar trend
was also observed for cyclins, where IP6 treatment of
cells resulted in a moderate decrease in cyclin E levels
(f20–30%; Figure 3E ) but a relatively stronger decrease
in cyclin D1 levels (f20–40%; Figure 3F ) at all doses and
time points studied; actin blot (Figure 3G) confirmed protein
loading.
Effect of IP6 on CDKI–CDK Binding and CDK Kinase
Activity in LNCaP Cells
Based on the findings showing that IP6 strongly induces
CDKIs Cip1/p21 and Kip1/p27 protein expression in LNCaP
cells, and the reports showing that such an induction in
CDKIs results in an increase in their interaction with CDKs
leading to a decrease in CDK kinase activity [36,44], we next
assessed whether IP6-caused increase in both Cip1/p21
and 2Kip1/p27 also leads to an increase in their interactions
with CDK2 and/or CDK4. To assess the effect of IP6 on
these bindings, cell extracts prepared under nondenaturing
Figure 2. Effect of IP6 on cell cycle progression of LNCaP cells. Cells were cultured under standard conditions and, in the first experiment (A–C), were treated with
0.5 to 4 mM IP6 for 24 and 48 hours. In the second experiment (D–F), under similar conditions, cells were treated with 1 and 2 mM IP6 for 6, 12, and 24 hours. At
the end of each treatment, cells were collected after a brief incubation with trypsin –EDTA followed by processing for cell cycle phase distribution, as detailed in
Materials and Methods section. In both experiments, the data shown are mean ± SE of three independent plates, which were reproducible in an additional
independent experiment.
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conditions and employed above for Western immunoblot-
ting of CDKIs, CDKs, and cyclins were subjected to immu-
noprecipitation using Cip1/p21 or Kip1/p27 antibody, and
immunoprecipitates were run on SDS-PAGE followed by
blotting. In the case of both Cip1/p21 and Kip1/p27, mem-
branes were probed with anti–CDK2 and anti–CDK4 anti-
bodies. As shown in Figure 4A, compared to controls,
IP6 treatment of cells resulted in an increased binding of
Cip1/p21 with both CDK2 and CDK4; similar results were
also evident for Kip1/p27 showing an increased binding with
both CDK2 and CDK4 following IP6 treatments (Figure 4A).
Together, these results suggest that an increased interac-
tion between induced levels of CDKIs (by IP6) with CDKs
plays an important regulatory role in possibly inhibiting CDK
kinase activity, leading to a G1 arrest in the cell cycle
progression of LNCaP cells.
To support the above suggestion, cell lysates prepared
from control and IP6-treated cells were subjected to immuno-
precipitation with anti–CDK2 or anti–CDK4 antibody fol-
lowed by kinase assays. As shown in Figure 4B, compared
to control, IP6 treatment of cells resulted in a strong decrease
(f80%) in CDK2 kinase activity as evidenced by a reduction
in phosphorylation of histone H1 used as substrate. Similarly,
IP6 also showed an inhibition in CDK4 kinase activity as
observed by a reduction in Ser780 and Ser807/811 phospho-
rylation of Rb fusion protein used as substrate (Figure 4C ).
IP6 Increases Hypophosphorylated Rb Levels by Decreas-
ing Rb Phosphorylation at Serine Residues in LNCaP Cells
An active CDK phosphorylates Rb at five different serine
residues and a threonine residue, releasing an E2F family
of transcription factors from the Rb–E2F complex that in-
duces expression of a number of genes required for S phase
transition [45–47]. Hyperphosphorylated Rb (ppRb) exerts
most of its cell cycle transition effects in a specific time frame
during the first two thirds of the G1 phase, where cells make
most decisions for proliferation versus quiescence [45–47].
Based on our results showing that IP6 strongly induces CDKI
levels and their increased interaction with CDKs, causing a
Figure 4. Effect of IP6 on CDKI–CDK binding and CDK kinase activity in
LNCaP cells. Cells at 60% confluency under standard culture conditions were
treated with different doses of IP6 for 12 or 24 hours, and cell lysates were
prepared in nondenaturing lysis buffer as detailed in Materials and Methods
section. For CDKI–CDK bindings (A), Cip1/p21 or Kip1/p27 was immuno-
precipitated from the total cell lysates and subjected to SDS-PAGE followed
by immunoblotting. The membranes in both cases were probed with anti –
CDK2 and anti –CDK4 antibodies followed by peroxidase-conjugated
appropriate secondary antibody and visualization by ECL detection system.
For CDK2 kinase activity (B), CDK2 was immunoprecipitated from the total
cell lysates and subjected to kinase assay in the presence of [c-32P] ATP and
histone H1 as substrate, as detailed in Materials and Methods section.
Samples were then subjected to SDS-PAGE followed by gel drying and
autoradiography. For CDK4 kinase activity (C), CDK4 was immunoprecipi-
tated from the total cell lysates and subjected to kinase assay in the presence
of ATP and Rb fusion protein as substrate, as detailed in Materials and
Methods section. Samples were then subjected to SDS-PAGE followed by
immunoblotting. The membranes were probed with phosphoserine-specific
Rb antibodies followed by peroxidase-conjugated appropriate secondary
antibody and visualization by ECL detection system. Different treatments are
as labeled in the figure.
Figure 3. Effect of IP6 on G1 cell cycle regulators in LNCaP cells. Cells were
cultured under standard conditions and, at 60% confluency, treated with
different doses of IP6 (1, 2, and 4 mM) for 12 and 24 hours. After these
treatments, cell lysates were prepared in nondenaturing lysis buffer and
subjected to SDS-PAGE followed by Western blot analysis, as detailed in
Materials and Methods section. Membranes were probed with anti –Cip1/p21
(A), anti –Kip1/p27 (B), anti –CDK2 (C), anti –CDK4 (D), anti –cyclin E (E),
anti – cyclin D1 (F), or anti –actin (G) antibody followed by peroxidase-
conjugated appropriate secondary antibody and visualization by ECL de-
tection system. Different treatments are as labeled in the figure.
IP6 Efficacy in LNCaP Prostate Cancer Cells Agarwal et al. 651
Neoplasia . Vol. 6, No. 5, 2004
strong decrease in the kinase activity of the latter, we next
assessed the effect of IP6 treatment on total Rb protein
levels, as well as any change in ppRb versus hypophos-
phorylated Rb (pRb). As shown in Figure 5A, IP6 treatment
of LNCaP cells resulted in an increase in the amount of total
Rb (ppRb plus pRb) at both 1 and 2 mM doses following
both 12 and 24 hours of treatment; however, this increase in
total Rb levels was due to an increase only in pRb levels
(fast-migrating lower band in the immunoblots) following IP6
treatment of the cells (Figure 5A). Based on these results
showing a strong increase in pRb levels by IP6 in LNCaP
cells, we next assessed whether this effect is due to a
change in Rb phosphorylation at specific Ser phosphoryl-
ation sites. Employing phospho-specific Rb antibodies in
immunoblotting, we observed that IP6 strongly decreases
the levels of Rb phosphorylated at Ser780 (Figure 5B) and
Ser807/811 (Figure 5C ); the equal protein loading in these
blots was conformed by actin immunoblotting (blot shown
just below Figure 5C ).
IP6 Decreases Transcription Factor E2F Levels in LNCaP
Cells
Transcription factor E2F family members (E2F1–E2F5)
play an important role in cell cycle progression following a
growth signal that phosphorylates Rb, releasing E2Fs free
from Rb-bound form [45,48–51]. Furthermore, it is the levels
of E2Fs that play a detrimental role in driving cell cycle
progression even in the free form [48–51]. Recently, it has
also been shown that knocking down the levels of cell cycle
regulators upstream of E2Fs is sufficient to inhibit E2F ex-
pression as well as cell growth [52]. Based on these reports
and our findings that IP6 strongly modulates CDKI–CDK–
cyclin levels, CDKI–CDK interaction, and the kinase activity
of CDKs together with a strong increase in hypoRb levels, we
next assessed the effect of IP6 on E2F protein levels. As
shown in Figure 5, compared to controls, IP6 treatment of
LNCaP cells resulted in a moderate to strong decrease in
the protein levels of different E2Fs. In case of E2F1, IP6
showed a f50% decrease following 24 hours of treatment
(Figure 5D); however, almost no change was observed in
E2F2 (Figure 5E ) and E2F3 (Figure 5F) protein levels
following IP6 treatments of cells. In case of E2F4, IP6
treatment for 24 hours resulted in f50% decrease only at
higher dose used in the study, but did not show any observ-
able changes at 12 hours of treatment (Figure 5G). Similarly,
higher IP6 dose (2 mM) and longer treatment time (24 hours)
also resulted in f70% decrease in E2F5 protein levels
(Figure 5H ). When the same blots were reprobed with
anti–actin antibody, they confirmed equal protein loading
(lower panel in Figure 5H ).
Effect of IP6 on Apoptosis Induction in LNCaP Cells
In addition to constitutively active mitogenic signaling as
well as alterations in cell cycle regulators’ expression and
function causing deregulated cell cycle progression, a loss of
apoptotic response due to constitutively active cell survival
and anti–apoptotic cascades are major hallmarks of various
human malignancies including PCA [36]. In this regard,
human prostate carcinoma LNCaP cells are an excellent
example as well as a model system where constitutively
active survival factor Akt plays an important role in their
survival even in this absence of growth factors [53,54].
These observations suggest that the agents that could
induce apoptotic death of cancer cells could be effective in
both cancer prevention and intervention. Based on our
studies showing strong efficacy of IP6 in LNCaP cells, we
next assessed whether this phytonutrient also induces apo-
ptotic death of LNCaP cells. As shown in Figure 6, treatment
of cells with IP6 at varying doses and time periods resulted
in a dose-dependent and time-dependent apoptotic death
at 12, 24, and 48 hours. The time points earlier (1, 3, and
6 hours) than 12 hours were also studied in these experi-
ments, but were not effective in causing apoptosis induction
Figure 5. Effect of IP6 on total Rb phosphorylation, serine residue–specific
Rb phosphorylation, and different E2F levels in LNCaP cells. Cells were
cultured under standard conditions and, at 60% confluency, treated with
different doses of IP6 (1 and 2 mM) for 12 and 24 hours. After these
treatments, cell lysates were prepared in nondenaturing lysis buffer and
subjected to SDS-PAGE followed by Western blot analysis, as detailed in
Materials and Methods section. Membranes were probed with anti – total Rb
(A), anti –phosphoserine780–specific Rb (B), anti –phosphoserine807/811–
specific Rb (C), anti –E2F1 (D), anti –E2F2 (E), anti –E2F3 (F), anti –E2F4
(G), anti –E2F5 (H), or anti – actin antibody followed by peroxidase-
conjugated appropriate secondary antibody and visualization by ECL
detection system. Different treatments are as labeled in the figure.
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(data not shown). Overall, IP6 treatment at 1 mM dose for
12 to 48 hours resulted in 1.6- to 2.2-fold increase (P < .05
to P < .01) in EF, a measure of apoptosis, compared to
controls (Figure 6). Comparable effects of IP6 were also
evident at 2 mM dose; however, its treatment at 4 mM
dose for 12, 24, and 48 hours resulted in a 2.4-, 5.0-, and
7.0-fold increase in apoptosis over control, respectively
(Figure 6).
Effect of IP6 on Bax and Bcl2 Levels and Their Ratio in
LNCaP Cells
The Bcl2 family includes both anti–apoptotic (e.g., Bcl2
itself) and pro–apoptotic (e.g., Bax) proteins, and the levels,
interaction, ratio, and translocation of different members in
this family determine the overall pro–apoptotic or anti–
apoptotic fate of the cell following an agent’s treatment
[55,56]. Based on our data showing that IP6 causes apopto-
tic death of LNCaP cells, we next assessed whether it is
associated with alterations in Bax and Bcl2 levels as well as
Bax versus Bcl2 ratio where an increase in this ratio favors
apoptosis [55,56]. As shown in Figure 7A, IP6 treatment of
cells at various doses (1–4 mM) for 12, 24, and 48 hours did
not show a noticeable alteration in Bax protein levels, but
resulted in a moderate to strong decrease in Bcl2 levels
(Figure 7B). The IP6 doses used in the study causedf60%
to 70%, 20% to 80%, and 60% to 70% decrease in Bcl2
levels following 12, 24, and 48 hours of treatments, respec-
tively (Figure 7B). Actin blotting confirmed the equal pro-
tein loading (Figure 7C ). Densitometric analysis of Bax and
Bcl2 immunoblots, followed by a calculation of Bax/Bcl2
ratio, showed that compared to controls, IP6 treatments for
12, 24, and 48 hours result in 2.2- to 3.3-fold, 1.5- to 5-fold,
and 2.4- to 3.3-fold increase in this ratio, respectively
(Figure 7D ), which possibly is one of the mechanisms of
Figure 6. Effect of IP6 on apoptotic induction in LNCaP cells. Cells were
cultured under standard conditions and treated with IP6 at 1, 2, or 4 mM dose
for various time points (12–48 hours). After these treatments, cells were
harvested and processed for the analysis of apoptotic DNA fragments using
Cell Death Detection ELISAplus kit and following the step-by-step protocol
provided by the manufacturer, as detailed in Materials and Methods section.
The data shown are mean ± SE of three independent samples, which were
reproducible in an additional independent experiment.
Figure 7. Effect of IP6 on Bax and Bcl2 levels and their ratio on LNCaP cells. Cells were cultured under standard conditions and, at 60% confluency, treated
with different doses of IP6 (1, 2, and 4 mM) for 12, 24, and 48 hours. After these treatments, cell lysates were prepared in nondenaturing lysis buffer and
subjected to SDS-PAGE followed by Western blot analysis, as detailed in Materials and Methods section. Membranes were probed with anti –Bax (A), anti –Bcl2
(B), or anti –actin (C) antibody followed by peroxidase-conjugated appropriate secondary antibody and visualization by ECL detection system. Different treatments
are as labeled in the figure. For determining Bax/Bcl2 ratio (D), immunoblots were scanned and arbitrary densitometric values for Bax and Bcl2 were employed
in the final calculations after correction for actin.
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the strong apoptotic effects of IP6 in LNCaP cells observed
in the present study (Figure 6).
Effect of IP6 on Constitutively Active Survival Factor Akt
and Associated Apoptosis in LNCaP cells
As mentioned earlier, survival factor Akt is constitutively
active in LNCaP cells, which make them survive even in the
absence of growth factors [53,54]. A couple of studies in
recent years have shown that a selective inhibition of PI3K
causes inhibition of constitutively active Akt in LNCaP cells
and induces their apoptotic death; however, a cotreatment
with growth factor partially reverses the apoptotic response
of PI3K inhibitors by activating other survival pathways
[53,54]. Based on these studies and our results showing
that IP6 causes apoptotic death of LNCaP cells, we next
assessed whether this agent also inhibits constitutively ac-
tive survival factor Akt and that such an affect is associated
with apoptosis response. The LNCaP cells were treated with
a PI3K inhibitor LY294002 or IP6 in serum-free medium as a
function of time, and total cell lysates were analyzed for
phospho-Akt and total Akt levels. Compared to LY294002
showing a complete inhibition in Akt phosphorylation as early
as 3 hours after treatment, IP6 at 2 and 4 mM doses did not
show any noticeable response at this early time point (data
not shown). However, similar treatments for 6 and 12 hours
resulted in a strong decrease in phospho-Akt levels at 4 mM
IP6 dose without any effect at 2 mM dose; the LY294002
PI3K inhibitor showed complete inhibition at these time
points, too (Figure 8A). The observed decrease in phos-
pho-Akt by IP6 and LY294002 was not due to an overall
decrease in total Akt, except in the case of LY294002
treatment for 12 hours (Figure 8B ).
Based on the observation that IP6 at higher dose reduces
phospho-Akt levels similar to PI3K inhibitor, we next
assessed its association with apoptosis induction. In case
of PI3K inhibitors, because cotreatment with growth factors
such as EGF partially reverses their apoptotic response, we
also employed similar experimental design to assess wheth-
er IP6 acts through similar a pathway(s). As shown in Fig-
ure 8C, compared to controls, LY294002 treatment of cells
for 12 and 24 hours resulted in four-fold increase (P < .001)
in EF; however, a cotreatment with EGF reduced (P < .01 at
12 hours and P < .05 at 24 hours, for LY294002 versus
EGF plus LY294002) the apoptotic response of LY294002
at both time points studied. In case of IP6 compared to
controls, it showed a f2.2- to 2.5-fold increase (P < .05) in
EF, which, unlike LY294002, was not reduced by similar
cotreatments with EGF (Figure 8C ). In fact, EGF plus IP6
treatment showed a further increase in EF (2.4- to 3.8-fold,
P < .05 compared to controls), although it was not statistically
Figure 8. Effect of IP6 on constitutively active Akt and associated apoptosis in LNCaP cells. Cells were cultured under standard conditions, and treated with PI3K
inhibitor LY294002 at 25 M dose, or different doses of IP6 (2 and 4 mM) for 6 and 12 hours under serum-free medium condition. After these treatments, cell
lysates were prepared in nondenaturing lysis buffer and subjected to SDS-PAGE followed by Western blot analysis, as detailed in Materials and Methods section.
Membranes were probed with anti –phospho-Akt (A) or anti – total Akt (B) antibody followed by peroxidase-conjugated appropriate secondary antibody and
visualization by ECL detection system. Different treatments are as labeled in the figure. In other experiments assessing apoptosis induction in LNCaP cells (C),
LNCaP cells were cultured under standard culture conditions and treated with PI3K inhibitor LY294002 (25 M), EGF (100 ng/ml), and IP6 (4 mM) either alone or
LY294002 plus EGF and IP6 plus EGF for 12 or 24 hours in serum-free medium. After these treatments, cells were harvested and processed for the analysis of
apoptotic DNA fragments using Cell Death Detection ELISAplus kit, as detailed in Materials and Methods section. The data shown are mean ± SE of three
independent samples, which were reproducible in an additional independent experiment.
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significant when compared to IP6 alone (Figure 8C). Togeth-
er, these results suggest that IP6 inhibits multiple compo-
nents of mitogenic and survival pathways compared to
selective PI-3K inhibitors such as LY294002 used in the
present study.
Discussion
The major findings in the present study are that IP6 inhibits
androgen-dependent human prostate carcinoma LNCaP cell
growth possibly through a G1 arrest in cell cycle progression,
and causes their apoptotic death. In this regard, it is impor-
tant to emphasize here that whereas IP6 showed a signifi-
cant cell growth inhibition at all the doses (0.5–4 mM) and
time points (24 and 48 hours) employed in the present
study, its effect on a G1 arrest was not evident earlier than
12 hours of treatment and was not sustained at 48 hours.
These observations suggest that, in part, a G1 arrest by
IP6 following 12 hours of its treatment drives the LNCaP
cells to a resultant growth inhibition and apoptotic death at
both early and late time points, and that other molecular
mechanisms such as an increased Bax/Bcl2 ratio and inhi-
bition in constitutively active Akt contribute additionally to its
strong efficacy in causing both growth inhibition and apop-
totic death of LNCaP cells at later time points. The doses of
IP6 (0.5–4 mM) showing strong efficacy in the present study
are those employed in the earlier cell culture studies (up to
5 mM IP6) by the present and other authors [10,19–22]. The
physiological and/or pharmacological significance of these
levels of IP6 in cell culture studies needs to be studied and
established clinically in the future; however, when these
cell culture concentrations of IP6 (with only single treatment)
are compared with published literature showing its anti–
cancer activity in animal models by using up to 15 mM
dose in continuous feeding in drinking water (reviewed in
Refs. [10,26,34]), the concentrations in cell culture studies
are much lower, clearly establishing their relevance in defin-
ing the molecular mechanism of IP6 efficacy at pharmaco-
logical doses at least in preclinical anti–cancer studies.
The regulation of cell cycle progression in eukaryotes is
controlled by CDKs, the activities of which are regulated by
interactions with their regulatory subunits (cyclins) and
CDKIs [36–40,44]. Cyclins and their cognate CDK catalytic
subunits noncovalently form complexes to produce the CDK
holoenzyme, which is activated by phosphorylation of cata-
lytic subunits through CDK-activating kinase [36–40,44].
CDK activities are specific to the distinct phases of the cell
cycle, where CDK4 complexed with D-type cyclins is respon-
sible for G1 phase progression; a complex of CDK2–cyclin E
is responsible for G1–S phase transition; CDK2–cyclin A
is required for S phase progression; and a complex of CDK1
(or cdc2)–cyclin B is needed for G2–M phase transition
[36–40,44]. CDK4–cyclin D1 and CDK2–cyclin E regulate
the phosphorylation of Rb protein and thus the level of
free E2Fs, thereby controlling the progression from G1 to
S phases of cell cycle [36–40,44]. The controlled cell
cycle progression is regulated, in part, by CDKIs (Cip1/p21,
Kip1/p27, and Kip2/p57) in response to both growth-stimu-
lating and growth-inhibitory signals [36–44]. CDKIs have
been shown to inhibit the kinase activity of CDK–cyclin
complexes that modulates Rb phosphorylation events, which
are essential for the transition at various cell cycle check-
points [36–44]. The unphosphorylated forms of Rb and its
related proteins have been shown to inhibit cell prolifera-
tion by sequestering the E2F family of transcription factors
[44–47]. The results obtained in our present study are
consistent with these reports related to the biologic role of
CDKIs, CDKs, and cyclins in driving cell cycle progression.
For example, we observed that IP6 causes a strong increase
in Cip1/p21 and Kip1/p27 levels, together with their in-
creased interaction (binding) with CDK2 and CDK4, and a
strong inhibition in CDK2 and CDK4 kinase activity. The
IP6 also caused a decrease in CDK4, cyclin D1, and different
E2Fs levels as well as Rb phosphorylation. All these alter-
ations in cell cycle regulators by IP6 involve those molecules
that govern a G1 to S phase transition and, therefore, the net
biologic outcome observed was indeed G1 arrest and growth
inhibition of LNCaP cells by IP6.
In human PCA patients, a decreased p27 expression has
been shown to be associated with aggressive phenotype of
prostatic carcinomas [57]. It has also been observed that
the loss of p21 function results into the failure of irradiation
response in PCA patients [57]. Mechanistic studies have
shown that a decrease in the expression and/or function of
these CDKIs could be mediated by DNA methylation, post-
transcriptional modification, and, most commonly, posttrans-
lational modification [58,59]. At posttranslational level,
altered subcellular localization of p27 and degradation by
the ubiquitin–proteosome pathway are observed in a num-
ber of human cancers [60–62]. An important role of CDKI
expression and function in human malignancies including
PCA is further supported by recent studies showing that
overexpression of Kip1/p27 or Cip1/p21 using adenoviral
approaches inhibits the growth of different types of tumors
[63–68]. Together, these findings suggest that Cip1/p21 and
Kip1/p27 are important molecular targets in the etiology of
various malignancies including PCA, and that the agents that
could induce their functional levels should be effective in
controlling human malignancies including PCA. In accord
with these suggestions, the results of our present study
showing a strong increase in Cip1/p21 and Kip1/p27 protein
levels by IP6 in LNCaP cells might be of high significance for
PCA control. More studies, however, are needed to define
the mechanisms of these CDKI induction by IP6 and to
establish a cause-versus-effector role of their induction in
G1 arrest and growth inhibition of LNCaP cells by IP6.
Several evidences suggest that apoptosis frequently
occurs in cells at the G1 phase of the cell cycle, and that
an arrest in late G1 or S phase could accelerate apoptosis
[69–71]. Accordingly, the proteins responsible for the G1 or
G1/S phase arrest, such as Kip1/p27 and Cip1/p21, could be
the logical targets in apoptotic events. In this regard, over-
expression of these CDKIs in cancer cells through adenoviral
vectors is shown to block all cyclin/CDK activities and to
induce both cell cycle arrest and apoptosis [71–77]. Consist-
ent with these reports, we also observed that IP6 causes an
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induction in Cip1/p21 and Kip1/p27, and inhibits CDK kinase
activity together with cell cycle arrest and apoptosis induc-
tion, suggesting a possible role of IP6-caused CDKI induc-
tion in its apoptotic activity.
The role of Bcl2 family members and their interplay
are well studied and established in apoptosis induction
[55]. With regard to Bcl2/Bax in apoptosis process, Bcl2 is
an anti–apoptotic molecule whereas Bax supports apopto-
sis. A homodimerization of Bcl2 is an anti–apoptotic effect;
however, recent studies have shown that serine/threonine
phosphorylation of Bcl2 inactivates it, which favors apoptosis
response [55,56]. When it heterodimerizes with Bax,
Bcl2 loses its anti–apoptotic function and causes apoptosis;
the better scenario for apoptosis is the homodimerization of
Bax [55,56]. Consistent with these reports, we observed that
IP6 treatment of LNCaP cells results in a decrease in the
levels of Bcl2 without any noticeable changes in Bax levels;
however, Bcl2 decrease was sufficient for a substantial
increase in Bax/Bcl2 ratio, a situation that favors apoptosis
[55,56]. Recent studies have also established the role of Bcl2
in mitochondrial damage causing apoptotic death [55,56].
Regarding Bax, published studies demonstrate that the pro–
apoptotic effects of Bax are tightly linked to its caspase
activation–dependent redistribution from the cytosol to the
mitochondrial membrane, which promotes dissipation of
mitochondrial membrane potential, cytochrome C release,
and subsequent caspase activation [55,56,78]. Based on
these studies and our data showing the effect of IP6 on Bcl2
decrease and Bax/Bcl2 ratio increase, more studies are
needed in the future to assess the effect of IP6 on Bcl2
family members and their interplay and subcellular distri-
bution in IP6-induced apoptosis. Additional studies are also
needed in the future to define whether IP6-mediated alter-
ations in Bcl2 levels and Bax/Bcl2 ratio activate mitochon-
drial damage, leading to cytochrome C release and
caspase activation in its overall apoptotic response in
LNCaP cells.
The requirement for membrane-associated cell survival,
and mitogenic and/or anti–apoptotic signaling is a universal
characteristic of cells [79–82]; however, both genetic and
epigenetic alterations lead to a persistent autocrine stimula-
tion of cells by secreted growth factors, which has been
implicated in a wide variety of human malignancies including
PCA [36,44,83]. PI3K is a ubiquitous lipid kinase composed
of a regulatory (p85) and a catalytic (p110) subunit, and is
involved in receptor signaling through tyrosine kinase recep-
tors regulating various important cellular processes such as
cell survival, growth, transformation, and so on [79–81].
Phosphatase and tensin homologue (PTEN), a tumor-sup-
pressor gene, antagonizes PI3K activity by dephosphorylat-
ing the D3 phosphate group of lipid second messenger.
Therefore, PTEN functions as a negative regulator of PI3K/
Akt pathway [79,82]; however, it is mutated or nonfunctional
in many cancer cells including human PCA LNCaP cells
[53,54]. PI3K catalyzes the phosphorylation of phosphoino-
sitol-4 phosphate and phosphoinositol-4,5 phosphate at D3
position, and activates various downstream elements includ-
ing Akt/protein kinase B; phosphorylation at Ser473 and
Thr308 is inducible and essential for Akt activation [84,85].
Inhibition of pro–apoptotic signals and induction of survival
signals lead to Akt activation, which may also contribute to
malignant transformation [84,85]. Both Cip1/p21 and Kip1/
p27 have been shown as targets of Akt for their phosphoryl-
ation and subsequent degradation, leading to progression of
cell cycle [86]. Bad and caspase 9 are other downstream
targets of Akt, the phosphorylation of which mediates anti–
apoptotic effect mainly through inhibition of mitochondrial
apoptosis through Akt signaling [85,87].
Together, the above studies suggest that inhibition of
constitutively active Akt signaling could be a potential target
to control PCA cell growth and induce apoptotic death. In this
regard, recent studies have shown that PI3K pathway is a
dominant growth factor–activated cell survival pathway in
human PCA LNCaP cells, where treatment of LNCaP cells
with PI3K inhibitors under serum-free conditions results in
apoptotic death, and that serum, several growth factors, or
androgen treatment, together with PI3K inhibitors, blocks
the apoptotic response of PI3K inhibitors [53,54]. In these
Figure 9. Proposed mechanisms of anticancer efficacy of IP6 associated with a G1 arrest in cell cycle progression and apoptosis induction in human prostate
carcinoma LNCaP cells.
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studies, an inhibition of MEK1 activation by PD98059 did not
cause apoptotic death [53,54]. Together, these studies sug-
gested that inhibition of PI3K activation, followed by AKT
activation, is sufficient for apoptotic death of LNCaP cells
only if other mitogenic responses are not activated. Further-
more, these studies also emphasize that inhibiting one
signaling pathway is possibly not enough to control the
growth of PCA cells and to induce their apoptotic death,
and that agents that exert diversified inhibitory effects on
both mitogenic and cell survival signaling in PCA cells,
leading to their growth inhibition and apoptotic death, are
needed. Consistent with these reports, in our studies, we
found that IP6 inhibits constitutively active Akt in LNCaP cells
together with their apoptotic death, and that cotreatment with
EGF does not reverse IP6-caused apoptotic death, in con-
trast to PI3K inhibitor where apoptosis is partially reversed by
EGF cotreatment. These observations suggest that IP6 has
diversified inhibitory effects on different mitogenic and sur-
vival signalings, causing both cell cycle arrest and apoptotic
death of LNCaP cells. Because Akt activation also targets
CDKIs phosphorylation and degradation leading to cell cycle
transition, it is plausible that IP6 inhibits Akt activation,
thereby causing CDKI accumulation followed by cell cycle
arrest in LNCaP cells as one of its mechanisms of efficacy,
other than its apoptotic effect through inhibition of Akt
activation causing caspases activation and molecular alter-
ations. In the future, more studies are needed in these
directions to further define the mechanisms of IP6 efficacy
in PCA cells.
Overall, the findings in the present study revealed the
anticancer efficacy of IP6 against hormone-dependent hu-
man PCA LNCaP cells, which involves inhibition of cell cycle
progression in G1 phase and an induction of apoptosis. IP6
upregulates CDKIs accompanied by its increased binding
with CDKs, causing a strong decrease in their kinase activity
(Figure 9). This further leads to a decrease in the hyper-
phosphorylated form of Rb with a concomitant increase in its
hypophosphorylated form, causing an increased binding of
E2Fs with pRb in the cytoplasm, thereby reducing their
transcriptional activity for growth-responsive genes. This
effect is also augmented by a decrease in some E2F levels
by IP6. Furthermore, IP6 inhibits Akt activation and showed
an overall increase in Bax/Bcl2 ratio, which might be prom-
inent mechanisms for the apoptotic death of PCA cells
(Figure 9). However, it would be interesting to investigate
in the future whether inhibition of Akt signaling by IP6 has any
role in the upregulation of CDKIs in LNCaP cells. More-
over, the translation of mechanism-based in vitro anticancer
efficacy of IP6 into in vivo condition in future studies would be
helpful in reducing the risk, as well as management and
control, of PCA in humans.
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